Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99694
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zinonos, I. | - |
dc.contributor.author | Labrinidis, A. | - |
dc.contributor.author | Liapis, V. | - |
dc.contributor.author | Hay, S. | - |
dc.contributor.author | Panagopoulos, V. | - |
dc.contributor.author | Denichilo, M. | - |
dc.contributor.author | Ponomarev, V. | - |
dc.contributor.author | Ingman, W. | - |
dc.contributor.author | Atkins, G. | - |
dc.contributor.author | Findlay, D. | - |
dc.contributor.author | Zannettino, A. | - |
dc.contributor.author | Evdokiou, A. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Anticancer Research: international journal of cancer research and treatment, 2014; 34(12):7007-7020 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.issn | 1791-7530 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99694 | - |
dc.description.abstract | Background/Aim: Drozitumab is a fully human agonistic monoclonal antibody that binds to death receptor DR5 and induces apoptosis. However, drozitumab resistance is a major obstacle limiting anticancer efficacy. Materials and Methods: We examined the potential for the chemotherapeutic agent doxorubicin to overcome resistance against drozitumab-resistant breast cancer cells both in vitro and in vivo. Results: Treatment with doxorubicin increased cell surface expression of DR5, reduced levels of Inhibitors of Apoptosis Proteins (cIAPs) and re-sensitised cells to drozitumab-induced apoptosis. Animals implanted with resistant breast cancer cells into the mammary fat pad and treated with a combination of drozitumab and doxorubicin showed inhibition of tumor growth and a substantial delay in tumor progression compared to untreated controls and mice treated with each agent alone. Conclusion: These results suggest that combination of drozitumab with chemotherapy and agents that modulate IAP levels could potentially be a useful strategy in the treatment of breast cancer. | - |
dc.description.statementofresponsibility | Irene Zinonos, Agatha Labrinidis, Vasilios Liapis, Shelley Hay, Vasilios Panagopoulos, Mark Denichilo, Vladimer Ponomarev, Wendy Ingman, Gerald J. Atkins, David M. Findlay, Andrew C. W. Zannettino and Andreas Evdokiou | - |
dc.language.iso | en | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.rights | Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved | - |
dc.source.uri | http://ar.iiarjournals.org/content/34/12/7007.abstract | - |
dc.subject | Apoptosis; Apo2L/TRAIL; drozitumab; drug resistance; chemotherapy; breast cancer | - |
dc.title | Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPS) | - |
dc.type | Journal article | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/627015 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Liapis, V. [0000-0002-2354-3521] | - |
dc.identifier.orcid | Panagopoulos, V. [0000-0002-6879-1262] | - |
dc.identifier.orcid | Ingman, W. [0000-0003-3116-2902] | - |
dc.identifier.orcid | Atkins, G. [0000-0002-3123-9861] | - |
dc.identifier.orcid | Zannettino, A. [0000-0002-6646-6167] | - |
dc.identifier.orcid | Evdokiou, A. [0000-0001-8321-9806] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.